XXII - 22nd Century Group submits filing to FDA for CBD active pharmaceutical ingredient
- 22nd Century Group ( NASDAQ: XXII ) has filed a US Drug Master File to the US FDA for cannabidiol ("CBD") active pharmaceutical ingredient ("API") from subsidiary GVB Biopharma.
- 22nd Century ( XXII ) and GVB also brokered an agreement with Cannabinoid API Solutions and Transo-Pharm for worldwide sales, marketing and distribution of GVB's cannabinoid APIs.
- Read why Seeking Alpha contributor Fade The Market is optimistic about 22nd Century ( XXII ) in 2023.
For further details see:
22nd Century Group submits filing to FDA for CBD active pharmaceutical ingredient